I'm LongbridgeAI, I can summarize articles.VG Health (VHT) fell 2.41% this week to close at $311.9, underperforming the S&P 500’s 0.27% dip by about 2.14 percentage points. The week was a fade from the start: Monday opened at $318.045 and hit a weekly high of $322 before closing at $320.740, then drifted lower through the week. Thursday broke below $312, and Friday traded down to $310.310 before settling at $311.9. The weekly range was 3.68%, and average daily volume of 177,130 shares ran about 10.
The Week
VG Health (VHT) fell 2.41% this week to close at $311.9, underperforming the S&P 500’s 0.27% dip by about 2.14 percentage points. The week was a fade from the start: Monday opened at $318.045 and hit a weekly high of $322 before closing at $320.740, then drifted lower through the week. Thursday broke below $312, and Friday traded down to $310.310 before settling at $311.9. The weekly range was 3.68%, and average daily volume of 177,130 shares ran about 10.8% below the 60-day median, so turnover was light. The price now sits below the 20-day moving average of $316.066 but above the 60-day at $313.948, leaving it in the middle of the recent range.
Sector News
The healthcare space was busy this week. Large-cap pharma dominated the headlines: Eli Lilly reported its new weight-loss drug helped more than half of patients lose 20% of body weight, with a third losing 25%, while its once-daily Orforglipron showed lower heart-disease risk. Merck struck a $2.13 billion KRAS deal and said its investigational skin drug tulisokibart met the primary endpoint in a Phase 2b study. AbbVie posted positive eczema and weight-loss candidate data, won EU approval for a paediatric Rinvoq indication, and received a buy rating from Scotiabank. Pfizer reported positive Phase 3 vitiligo results for LITFULO but also faces a Florida lawsuit over COVID-19 vaccine claims. On the sector level, US drugmakers turned to China for licensing deals and the industry doubled down on AI to cut costs. VG Health still closed lower in four of five sessions despite the dense news flow.
The Week Ahead
Macro data dominates the early part of next week. On Monday, 5 October, the US S&P Global services PMI final and ISM non-manufacturing PMI are due, with the ISM prior at 55.4 and a 55 forecast. Tuesday brings international trade data, with the prior deficit at -88.6 and a -102 estimate, plus the goods trade balance revision. Healthcare investors will also watch for follow-through from this week’s clinical readouts and deal activity, especially how Eli Lilly’s obesity data and Pfizer’s litigation continue to shape sentiment.
In Short
VG Health gave back 2.41% against a busy medical-sector news week, with the price still holding within its 60-day range of $296.385 to $330.75 rather than breaking down. Valuation remains mixed: price-to-book is 1.520 while earnings are negative, and the latest session’s flow showed large-lot money as a net seller against net buying from small and medium lots. That split leaves direction unresolved. The next focus is whether healthcare regains attention after the macro readings and clinical updates, and how the price behaves around the 60-day moving average.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.